• InterMune Inc., of Brisbane, Calif., reported net revenue in the third quarter of $7.5 million from sales of Esbriet (pirfenidone) for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF). The majority of revenues were derived from Germany (approximately 91 percent), the first country in which the product was launched in September 2011. Net loss was $45.4 million, or $0.70 per share, compared with a net loss of $38.2 million, or $0.63 per share, in the same quarter of 2011. Net loss for the first nine months of 2012 was $91.5 million, or $1.41 per share, compared with a net loss of $110.2 million, or $1.88 per share, in the first nine months of 2011. As of Sept. 30, the company had cash and cash equivalents of approximately $351.4 million.